High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients

Acta Oncol. 2017 Jan;56(1):104-106. doi: 10.1080/0284186X.2016.1262548. Epub 2016 Dec 6.

Authors

Leena Vehmanen¹, Juho Suojanen², Risto Kontio², Tapio Utriainen¹, Carl Blomqvist¹

Affiliations

¹ a Department of Oncology , Helsinki University Central Hospital , Helsinki , Finland.
² b Department of Oral and Maxillofacial Surgery , Helsinki University Central Hospital , Helsinki , Finland.

PMID: 27921521
DOI: 10.1080/0284186X.2016.1262548

No abstract available

MeSH terms

Bone Density Conservation Agents / adverse effects*
Denosumab / adverse effects*
Follow-Up Studies
Humans
Jaw Diseases / chemically induced*
Male
Neoplasm Grading
Neoplasm Staging
Osteonecrosis / chemically induced*
Prognosis
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / secondary
Retrospective Studies

Substances

Bone Density Conservation Agents
Denosumab